Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 225-533-8 | CAS number: 4904-61-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Description of key information
Oral
2002: According to OECD 422; GLP; 10 Sprague Dawley rats; 30, 100, 300 mg/kg bw/day; no mortality; NOAEL males and females: 300 mg/kg bw/day, reproduction. (K1)
Link to relevant study records
- Endpoint:
- one-generation reproductive toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Version / remarks:
- 1986
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- other: Crl:CD (SD)IGS BR
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ORGANISMS
- Age: males 59 days, females 52 days (approximately) - Route of administration:
- oral: gavage
- Details on exposure:
- ADMINISTRATION / EXPOSURE
- Vehicle: corn oil
- Concentration in vehicle: 6, 20, 60 mg/ml
- Total volume applied: 5 ml/kg bw/dose - Details on mating procedure:
- MATING PROCEDURES:
- mating period approximately 1-2 weeks, beginning after approximately four weeks of dosing. - Duration of treatment / exposure:
- Exposure period: males through test day 55; females 4 weeks premating through 4-day lactation period
Premating exposure period (males): approximately 4 weeks
Premating exposure period (females): approximately 4 weeks
Duration of test: approximately 60 days - Frequency of treatment:
- daily
- Dose / conc.:
- 30 mg/kg bw/day
- Dose / conc.:
- 100 mg/kg bw/day
- Dose / conc.:
- 300 mg/kg bw/day
- No. of animals per sex per dose:
- Number of animals: 10 per sex and per dose group
- Control animals:
- yes, concurrent vehicle
- Parental animals: Observations and examinations:
- - Clinical signs: at least once daily
- Mortality: at least twice daily
- Body weight: weekly, for females also on lactation days 0 and 4
- Food consumption: weekly
- Ophthalmoscopic examination: Both eyes of all rats prior to study and on test day 24, prior to clinical pathology evaluation (surviving rats).
- Clinical pathology evaluation on all rats after 4 weeks of dosing, and on male rats at the time of scheduled sacrifice:
- hematology / coagulation: erythrocyte count, total leukocyte count, platelet count, hemoglobin concentration, hematocrit, differential leukocyte count, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, absolute reticulocyte counts, red cell distribution width, microscopic blood examination, activated partial thromoboplastin time, prothrombin time.
- clinical chemistry: alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, sorbitol dehydrogenase, glucose, urea nitrogen, calcium, inorganic phosphorus, total bilirubin, cholesterol, triglyceride, creatinine, total protein, albumin, globulin, sodium, potassium, chloride.
- urine: volume, specific gravity, urobilinogen, blood, glucose, protein, appearance (quality, transparency, color), pH, bilirubin, ketones, sediment microscopy.
- Other: Neurobehavioral Functional Observational Battery (FOB) on all study rats prior to exposure and following approximately 4 weeks of test substance administration. - Litter observations:
- OFFSPRING: gestation length, mating index, gestation index, fecundity index, implantation site numbers, implantation efficiency, sex ratio, pups born alive, viability index
- Postmortem examinations (parental animals):
- ORGANS EXAMINED AT NECROPSY (MACROSCOPIC AND MICROSCOPIC):
- Time: Sacrifice and necropsy of males on day 56 and of females on days 56-64.
- Organ weights P: liver, kidneys, adrenal glands, thymus, brain, spleen, heart, testes, epididymides. Calculation of ratios to final body and brain weights.
- Histopathology P: all high dose and control rats: testes, epididymides, ovaries, gross lesions; 5 high dose and 5 control rats per sex: additional 37 tissues 5 females from other groups with >= 1 offspring: liver - Postmortem examinations (offspring):
- Implantation site number and efficiency, sex ratio, mean pup weights, pups born alive, viability index
- Statistics:
- STATISTICAL METHODS:
- All weight parameters (P, not F), gestation length, clinical pathology, grip strength, foot splay: One-way analysis of variance followed with Dunnett's test or Kruskal-Wallis test; followed with Dunn's test.
- Incidence of clinical and FOB observations; mating, gestation, fecundity indexes: Sequential application of Cochran-Armitage test for trend
- Implantation site number and efficiency, sex ratio, pups born alive, viability index: Jonckheere's test
- Mean pup weights: Linear contrast of the least square means
- Motor activity: Levene's and Shapiro-Wilk tests followed by repeated measures analysis of variance followed by contrasts of Jonckheere's trend test. - Clinical signs:
- no effects observed
- Description (incidence and severity):
- There were no test substance-related effects on clinical observations
- Mortality:
- mortality observed, non-treatment-related
- Description (incidence):
- One high-dose male was sacrificed in extremis due to a dosing-related injury. One high-dose female was found dead on day 57 from dystocia. No other deaths occured during the study.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Decreased body weight gain was observed and considered to be compound-related and of biological significance: 300 mg/kg males (-19 % for days 1-56, not statistically significant; weight -7%); 100 and 300 mg/kg females (only during gestation: gains -13% and -20%, weights -7% and -12%, respectively, statistically significant).
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- Increased food consumption was observed and considered to be compound-related and of biological significance: 300 mg/kg males (+19%) 100 mg/kg (+7%, not statistically significant) and 300 mg/kg females (+13%, statistically significant) during gestation.
- Food efficiency:
- effects observed, treatment-related
- Description (incidence and severity):
- As a consequence, food efficiency was significantly reduced: 300 mg/kg males (-33%) 100 and 300 mg/kg females during gestation (+14 and +29%, respectively, statistically significant).
- Ophthalmological findings:
- no effects observed
- Description (incidence and severity):
- no test substance-related effects
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- no test substance-related effects
- Clinical biochemistry findings:
- no effects observed
- Behaviour (functional findings):
- no effects observed
- Description (incidence and severity):
- There were no test substance-related effects in neurobehavioral parameters or motor activity.
- Organ weight findings including organ / body weight ratios:
- effects observed, non-treatment-related
- Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- no test substance-related adverse effects
- Reproductive function: oestrous cycle:
- not examined
- Reproductive function: sperm measures:
- not examined
- Reproductive performance:
- no effects observed
- Description (incidence and severity):
- - Fertility index: no test substance-related effects
- Duration of gestation: no test substance-related effects
- Gestation index: no test substance-related effects
- Number of implantations: no test substance-related effects
- Mating index: no test substance-related effects;
- Implantation efficiency: no test substance-related effects - Dose descriptor:
- NOAEL
- Effect level:
- 300 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- reproductive performance
- other: no adverse effects observed
- Dose descriptor:
- NOAEL
- Effect level:
- 100 mg/kg bw/day
- Sex:
- male
- Basis for effect level:
- body weight and weight gain
- food consumption and compound intake
- food efficiency
- Dose descriptor:
- NOAEL
- Effect level:
- 30 mg/kg bw/day
- Sex:
- female
- Basis for effect level:
- body weight and weight gain
- food consumption and compound intake
- food efficiency
- Critical effects observed:
- no
- Mortality / viability:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Body weights of pups in the 300 mg/kg group were significantly decreased (-17% on lactation day 4)
- Other effects:
- no effects observed
- Description (incidence and severity):
- - Sex and sex ratios: no test substance-related effects
- Pups born alive: no test substance-related effects - Dose descriptor:
- NOAEL
- Generation:
- F1
- Effect level:
- 100 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- body weight and weight gain
- Critical effects observed:
- no
- Reproductive effects observed:
- no
Reference
- NOAEL 30 mg/kg for females, 100 mg/kg for males
- LOAEL 100 mg/kg for females, 300 mg/kg for males
- LOAEL 300 mg/kg for pups
Summary of reproductive outcomes:
- Dose (mg/kg) 0 30 100 300
- Mating Index(%): 80.0 90.0 100.0 100.0
- Fertility Index (%): 87.5 77.8 70.0 70.0
- Gestation Length (days): 22.0 22.0 22.0 22.0
- Implantations (mean/litter): 16.0 15.6 16.3 16.1
- Implantation efficiency (%): 92.1 96.2 92.0 89.5
- Gestation Index: 100.0 100.0 100.0 100.0
- Mean % Born Alive: 98.3 99.1 99.2 99.0
- 0-4 Day Viability (%): 98.0 99.0 98.2 98.3
- Sex Ratio (males): 0.45 0.50 0.49 0.45
Effect on fertility: via oral route
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 60 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
Effect on fertility: via inhalation route
- Endpoint conclusion:
- no study available
Effect on fertility: via dermal route
- Endpoint conclusion:
- no study available
Additional information
Oral
A combined repeated dose toxicity study with the reproduction/developmental toxicity screening test (no limit test) was performed according to OECD 422 and in compliance with GLP. Ten Sprague Dawley rats per sex per dose were treated daily orally by gavage with 30, 100, or 300 mg/kg bw/day of the test substance equivalent to 6, 20, and 60 mg/ml concentration in vehicle, respectively. The vehicle used was corn oil. The total volume applied was 5 ml/kg bw/dose. Males and females were exposed through test day 55 and from four weeks pre-mating through 4-day lactation period, respectively. Control animals were included and received concurrent vehicle treatment. General toxicity has been stated in the endpoint summary of chapter 7.5. Subsequently, only reproductive and developmental effects are presented. No effects regarding fertility, duration of gestation, gestation index, number of implantations, mating index, or implantation efficiency were observed in parental animals. No effects on viability of pups was observed. Body weights of pups in the 300 mg/kg/day group were significantly decreased (-17% on lactation day 4). No substance related changes were reported for sex and sex ratio and pups born alive. The NOAEL in pups was 100 mg/kg/day, based on decreased body weights of pups in the 300 mg/kg/day group during gestation (2000, K1).
In addition, a combined repeated dose/reproductive developmental toxicity study in Sprague Dawley rats treated orally with test substance was only available in the original study language (Japanese) and an IUCLID dossier entry available on the NIHS Japan was used (2007, K4). Results obtained in this study are similar to those retrieved by Malley et al. (2002). However, effects on the liver were here regarded as adverse. It has to be noted that no historical ranges of the control were given and results were not properly discussed in the IUCLID dossier entry. Thus, it may be assumed that effects on the liver were adaptive and a non-adverse reaction as has been concluded for effects on the liver by Malley et al. (2002). In addition, the significant low value of the number of liveborn pups at 300 mg/kg bw/day was regarded as adverse. However, the basis for effect level (here: significant lower value of the number of liveborn pups at 300 mg/kg bw/day) does not take the number of stillborn pups into account which are higher in the control group than in the 300 mg/kg bw/day group. Thus, a live birth index of 100% in the 300 mg/kg bw/day group was achieved compared to 98.7% in the control group. Taking the live birth index into account, the finding of decreased liveborn pups was not considered as test substance-related and adverse.
Effects on developmental toxicity
Description of key information
Inhalation:
2003: No guideline followed; GLP; whole body inhalation; 22 Sprague Dawley rats; 10, 25, 67 ppm; Decreased fetal body weight and increase in delayed sternebral ossification at 67 ppm; NOEC maternal and fetal developmental toxicity: 67 ppm and 25 ppm (K1)
Link to relevant study records
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- test procedure in accordance with generally accepted scientific standards and described in sufficient detail
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Version / remarks:
- 1981
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OTS 798.4900 (Prenatal Developmental Toxicity Study)
- Version / remarks:
- 1987
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- other: Crl:CD (SD)BR
- Details on test animals or test system and environmental conditions:
- TEST ORGANISMS
- Source: Charles River Breeding Laboratories, Raleigh (North Carolina, USA)
- females; age: 51-70 days when received (at 1, 2, or 3 days of gestation); 5, 4, or 3 days acclimation
- Number of animals: 22 per exposure concentration - Route of administration:
- inhalation: mixture of vapour and aerosol / mist
- Type of inhalation exposure (if applicable):
- whole body
- Vehicle:
- air
- Details on exposure:
- ADMINISTRATION / EXPOSURE
- Type of exposure: whole-body
- Concentrations: 10 / 25 / 75 ppm (target)
- Type or preparation of particles: Controlled flows of high-pressure air and liquid test substance through heated mixing flask (approx. 240 °C), dilution with additional air, total airflow 60 l/min (target; measured: 59 - 62 l/min).
- Exposure chamber temperature: target 22 +/- 2 °C; measured 22 - 27 °C - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- - Concentration monitoring: known volume samples from breathing zone at 60 minute intervals; passage through glass fiber filter followed by glass impinger with hexane as collection medium; weighing of filter before and after sampling; GC / FID analysis of hexane solution, quantification with standard curve.
- Particle size (high test concentration, 3 measurements): MMAD 5.4 / 1.5 / 0.76 µm, mean 2.6 µm, with 13-56% of the particles < 1 µm; 35-89% < 3 µm; 66-99% < 10 µm.
-further details: see references - Details on mating procedure:
- -mated by supplier
- Duration of treatment / exposure:
- days 6-20 of gestation
- Frequency of treatment:
- 6 hours/day
- Duration of test:
- Duration of test: 16 days
- Dose / conc.:
- 10 ppm (nominal)
- Remarks:
- 67.5 mg/m311, 10 +/- 0.27 ppm (analytical concentration)
- Dose / conc.:
- 25 ppm (nominal)
- Remarks:
- 169 mg/m3; 25 +/- 0.33 ppm (analytical concentration)
- Dose / conc.:
- 67 ppm (nominal)
- Remarks:
- 452 mg/m3; 67 +/- 1.9 ppm (analytical concentration)
- No. of animals per sex per dose:
- 22 per exposure concentration
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Rationale for animal assignment: Exposure concentrations were based on results of a 14-day inhalation study with the test substance. Groups of 10 non-pregnant female rats were exposed to either 18, 40, or 85 ppm (6 h/day) for 5 days. Slight effects (body weight gain reductions) were seen at 40 and 85 ppm.
- Sex: female - Maternal examinations:
- PARAMETERS ASSESSED DURING STUDY:
- Body weight gain: days 0, 6, 8, 10, 12, 14, 16, 18, 20, 21
- Food consumption: days 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 21
- Clinical observations: once daily (before onset of exposure; including day 21), on exposure days also 1 h after exposure
ORGANS EXAMINED AT NECROPSY (MACROSCOPIC AND MICROSCOPIC): Study terminated on day 21
- Macroscopic: Organs of the thoracic and abdominal cavities - Ovaries and uterine content:
- - Examination of uterine content: type (live and dead fetuses, and resorptions) and relative positions
- Fetal examinations:
- - Examination of fetuses: body weight, sex, and external alterations; visceral alterations and stages of renal papillary development (live fetuses 1, 3, 5 etc. for each litter), skeletal alterations (all live fetuses)
- Statistics:
- STATISTICAL METHODS:
- Maternal weight, weight change, food consumption: parametric linear contrast of means
- Incidence data (pregnancy, clinical observations): Cochran-Armitage test
- Reproductive outcome data and fetal alteration data: Jonckheere's test; at > 75 % ties: permutation methodology
- Mean fetal weight, sex ratio: Analysis of variance (ANOVA), applying a parametric linear contrast of least square means - Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- 10 ppm: no effect; 25 ppm: increase in facial staining; 67 ppm: diminished response to alerting stimulus; stained and/or wet fur, staining was considered to be the result of increased lacrimation and salivation and decreased grooming.
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Statistically significant effects in both absolute and adjusted (terminal body weight minus the products of conception) were observed at 25 and 67 ppm. Reductions were first noted on day 8 of gestation and persisted until study termination. The magnitude of the reductions from control values ranged from 5 to 6% and 11 to 16% at 25 ppm and 67 ppm, respectively. During the first week of exposure some occasionally statistically significant weight change intervals at 10 ppm were observed, however, were minimal in magnitude (3-4% lower than controls) and transient. Thus, were not considered to be adverse.
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- The maternal weight data corresponded to food consumption values, which were reduced at 25 (-9%) and 67 (-28%) ppm but unaffected at 10 ppm.
- Number of abortions:
- no effects observed
- Description (incidence and severity):
- Number aborting: none
- Pre- and post-implantation loss:
- no effects observed
- Description (incidence and severity):
- none
- Early or late resorptions:
- no effects observed
- Description (incidence and severity):
- - Number of resorptions (mean): 0 ppm: 1.0; 10 ppm: 0.7; 25 ppm: 0.4; 67 ppm: 0.7 ==> no effect
- Changes in number of pregnant:
- no effects observed
- Description (incidence and severity):
- - Number pregnant per dose level = number of litters: 0 ppm: 21; 10 ppm: 20; 25 ppm: 22; 67 ppm: 20. ==> no effect
- Other effects:
- no effects observed
- Description (incidence and severity):
- - Number of implantations (mean): 0 ppm: 14.1; 10 ppm: 14.1; 25 ppm: 13.3; 67 ppm: 13.8 ==> no effect
- Number of corpora lutea (mean): 0 ppm: 15.6; 10 ppm: 15.4; 25 ppm: 14.8; 67 ppm: 15.0 ==> no effect - Dose descriptor:
- NOEC
- Effect level:
- 10 ppm
- Based on:
- test mat.
- Basis for effect level:
- body weight and weight gain
- Remarks on result:
- other: more than 10% reduction in body weight implies maternal toxicity
- Abnormalities:
- no effects observed
- Reduction in number of live offspring:
- no effects observed
- Description (incidence and severity):
- - Number viable: all live
- Changes in sex ratio:
- no effects observed
- Description (incidence and severity):
- male/total = 0.53 / 0.52 / 0.50 / 0.49 ==> no effect
- Changes in litter size and weights:
- effects observed, treatment-related
- Description (incidence and severity):
- - Litter size and weights (mean): 0 ppm: 13.1 fetuses (6.9 males + 6.2 females) with 5.68 g mean weight 10 ppm: 13.4 fetuses (7.1 males + 6.4 females) with 5.63 g mean weight 25 ppm: 13.0 fetuses (6.6 males + 6.4 females) with 5.55 g mean weight 67 ppm: 13.1 fetuses (6.5 males + 6.7 females) with 4.93 g mean weight ==> statistically significant effect on weight (-13.2%) at 67 ppm
- External malformations:
- no effects observed
- Skeletal malformations:
- effects observed, treatment-related
- Description (incidence and severity):
- Compound related, statistically significant increase in incidence of delayed skeletal ossification:
- sternebrae: 0 ppm: -; 10 ppm: 1 fetus; 25 ppm: 2 fetuses (2 litters); 67 ppm: 8 fetuses (5 litters): considered compound-related and consistent with reduced fetal weight.
- vertebrae: 0 ppm: 113 fetuses (21 litters) 10 ppm: 123 (20); 25 ppm: 134 (22); 67 ppm: 136 (20): not considered toxicologically relevant based on high background incidence; well within the control range of four studies from the same time: 128-161 fetuses in 23-25 litters. - Visceral malformations:
- no effects observed
- Dose descriptor:
- NOEC
- Effect level:
- 25 ppm (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- fetal/pup body weight changes
- other: significant increase in delayed sternebral ossification at 67 ppm
- Abnormalities:
- effects observed, treatment-related
- Localisation:
- other: delayed sternebral ossification
- Description (incidence and severity):
- 8 fetuses (5 litters)
- Developmental effects observed:
- yes
- Lowest effective dose / conc.:
- 67 ppm (nominal)
- Treatment related:
- yes
- Relation to maternal toxicity:
- developmental effects as a secondary non-specific consequence of maternal toxicity effects
- Dose response relationship:
- no
- Conclusions:
- Developmental toxicity was only observed after exposure concentrations producing signs of maternal toxicity and thus, the test substance was not considered to be a selective developmental toxicant in the rat under the conditions chosen.
Reference
Table 1: Maternal body weights in rats exposed to the test substance by inhalation on days 6 to 20 of gestation
concentration (ppm)
Days of gestation |
0 N=2l |
10 N=20 |
25 N=22 |
67 N=20 |
0 |
239.7 (10.1)a,b |
240.8 (9.9) |
240.4 (12.0) |
240.4 (10.1) |
4 |
252.7 (14.0) |
249.2 (15.4) |
253.5 (14.2) |
254.7 (13.1) |
6 |
262.7 (13.8) |
257.3 (16.1) |
263.1 (16.6) |
256.4 (16.6) |
8 |
267.6 (12.7) |
255.9 (14.3)d |
253.7 (12.9)d |
239.3 (12.4)d |
10 |
277.0 (13.9) |
267.5 (11.l)d |
264.5(13.4)d |
245.2 (10.9)d |
12 |
289.6 (13.7) |
279.5 (11.8)d |
275.8 (15.2)d |
251.5 (12. l )d |
14 |
302.7 (15.3) |
293.6 (14.2) |
285.8 ( 16.6)d |
260.2 (12.8)d |
16 |
322.8 (16.8) |
315.2 (15.1) |
306.8 (17.4)d |
275.5 (14.9)d |
18 |
350.8 (17.9) |
344.3 (16.3) |
332.8 (17.9)d |
295.4 (16.l)d |
20 |
383.7 (20.7) |
374.8 (19.0) |
360.4 (21.4)d |
320.4 (18.6)d |
21 |
416.9 (22.9) |
408.0 (20.9) |
395.0 (22.5)d |
355.2 (22.6)d |
21C |
323.4 (19.6) |
313.5 (15.1) |
305.2 (17.4)d |
274.9 (18.9)d |
6-21 |
154.3 (21.4) |
150.8 (17.2) |
131.9 (23.8)d |
98.8 (23.4)d |
6-2lc |
60.8 (17.9) |
56.3 (14.4) |
42.1 (18.2)d |
18.5 (21.l)d |
a = Data from non-pregnant females were excluded
b = Standard deviation is presented in parentheses
c = Weight calculated using the final body weight minus the products of conception
d = Significant trend (linear contrast of means); p < 0.05
Effect on developmental toxicity: via oral route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via inhalation route
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEC
- 165.79 mg/m³
- Study duration:
- subacute
- Experimental exposure time per week (hours/week):
- 42
- Species:
- rat
Effect on developmental toxicity: via dermal route
- Endpoint conclusion:
- no study available
Additional information
Inhalation
In a developmental toxicity study (no limit test), 22 Sprague Dawley rats were exposed whole body to a mixture of aerosol and vapor of the test substance at concentrations of 10, 25, and 67 ppm. Females were mated by the supplier and exposed from gestation day 6 throughout day 20 six hours per day each day. The duration of the test was 16 days. Control animals receiving the concurrent vehicle (air) were included. Parameters examined were body weight, food consumption, uterine content, and clinical observations. Necropsy has been performed at study termination on day 21. An examination of the fetuses was conducted on body weight, sex, external alterations, visceral alterations, stages of renal papillary development, and skeletal alterations. No mortality or clinical signs were observed in maternal animals. Reduced maternal body weight was first noted on day 8 of gestation at 25 and 67 ppm and the reductions persisted until study termination. The magnitude of reductions from control values ranged from 5 to 6% at 25 ppm and 11 to 16% at 67 ppm. Although there were some occasionally statistically significant weight change intervals at 10 ppm during the first week of exposures they were minimal in magnitude (3-4% lower than controls) and transient and thus, were not considered to be adverse. The maternal weight data corresponded to food consumption values, which were reduced at 25 (-9%) and 67 (-28%) ppm but unaffected at 10 ppm. In maternal animals, no developmental toxicity was observed. Developmental toxicity was seen only at 67 ppm limited to a slight but statistically significant reduction in fetal body weight. In addition, a significant increase in delayed sternebral ossification that was consistent with the reduction in mean fetal body weight was observed. Litter sizes, viability, and sex ratios were unaffected. No gross external, visceral, or skeletal malformations were observed in fetuses. There was no evidence of fetal developmental toxicity at either 10 or 25 ppm. Thus, the NOEC for maternal developmental toxicity and fetal developmental toxicity was concluded to be 67 ppm and 25 ppm, respectively (2003, K1).
However, small reduction in fetal body weight and retardation of ossification where directly associated with high reduction of body weight of maternal animals (above 10% reduction) and regarded as secondary to maternal toxicity. Thus, no classification for developmental effects were warranted according to Regulation (EC) 1272/2008.
Justification for classification or non-classification
The available experimental test data are reliable and suitable for classification purposes under Regulation 1272/2008. As a result the substance is not considered to be classified for reproductive toxicity under Regulation (EC) No. 1272/2008.
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.